Drug Trial Radar · NCT07376889
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,096
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- Intermountain Health Care, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Conditions
- Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)Drug
Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.
Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)Drug
Vancomycin or daptomycin, per discretion of the treating physician
Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)Drug
Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem
Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)Drug
Daptomycin plus ceftaroline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Desirability of Outcome Ranking (DOOR)Time frame: From enrollment to 30 days post enrollment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Platte Valley Hospital
Brighton, Colorado · Recruiting
Saint Joseph Hospital
Denver, Colorado · Recruiting
St. Mary's Regional Hospital
Grand Junction, Colorado · Recruiting
Good Samaritan Hospital
Lafayette, Colorado · Recruiting
Lutheran Medical Center
Wheat Ridge, Colorado · Recruiting
St. Vincent Regional Hospital
Billings, Montana · Recruiting
St. James Hospital
Butte, Montana · Recruiting
Holy Rosary Hospital
Miles City, Montana · Recruiting
Intermountain Medical Center
Murray, Utah · Recruiting
McKay-Dee Hospital
Ogden, Utah · Recruiting
Utah Valley Hospital
Provo, Utah · Recruiting
LDS Hospital
Salt Lake City, Utah · Recruiting
St. George Regional Hospital
St. George, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.